NEW YORK – Natera said on Friday that its Signatera molecular residual disease test will be used in the DARE study, a multi-center clinical trial of palbociclib (Pfizer's Ibrance).
Palbociclib is a CDK4/6 inhibitor for the treatment of hormone receptor-positive, HER2-negative advanced breast cancer in combination with an aromatase inhibitor or fulvestrant.